Author： Neymark N.
Publisher： Adis International
ISSN： 1170-7690
Source： PharmacoEconomics, Vol.20, Iss.7, 2002-01, pp. : 485-497
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Paclitaxel vs cyclophosphamide, + cisplatin, for ovarian cancer
Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. :
Access to resources
Recommend
Paclitaxel plus cisplatin and lonidamine showed `good activity' in advanced ovarian cancer
Inpharma, Vol. 1, Iss. 1285, 2001-01 ,pp. :
Paclitaxel plus cisplatin increases survival, costs in ovarian cancer
Inpharma, Vol. 1, Iss. 1345, 2002-01 ,pp. :
Paclitaxel plus cisplatin increases survival, costs in ovarian cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 370, 2002-01 ,pp. :